LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Future oncology"
DOI: 10.2217/fon-2022-0802
Abstract: The first-in-class, small molecule HIF-2α inhibitor, belzutifan, has demonstrated promising antitumor activity in previously treated patients with clear cell renal cell carcinoma (RCC). HIF-2α also regulates VEGF expression and is involved in resistance to anti-VEGF therapy.… read more here.
Keywords: cell carcinoma; renal cell; anti therapy; therapy ... See more keywords